Perineural or intravenous dexamethasone for adductor canal and interspace block between the popliteal artery and posterior knee capsule blocks in total knee arthroplasty: a randomized trial
Pain Medicine · 2026-10-19
DOI: 10.1093/pm/pnag140 ↗Abstract
Abstract Importance Total knee arthroplasty causes substantial postoperative pain. Combined adductor canal and interspace block between the popliteal artery and posterior knee capsule (iPACK) provides motor-sparing analgesia, but its duration is limited. Objective To compare perineural and intravenous dexamethasone as adjuncts to adductor canal and iPACK blocks in older patients undergoing primary total knee arthroplasty. Design Prospective, randomized, quadruple-blind, parallel-group trial. Setting Wiktor Dega Orthopaedic and Rehabilitation Clinical Hospital, Poznan University of Medical Sciences, a tertiary referral hospital in Poznan, Poland. Participants Ninety patients aged 65-100 years undergoing primary total knee arthroplasty. Intervention(s) or exposure(s) Patients were allocated equally to receive adductor canal and iPACK blocks with ropivacaine plus perineural dexamethasone 4 mg in total (2 mg per block), intravenous dexamethasone 4 mg, or placebo. Main outcome(s) and measure(s) The primary outcome was time to first rescue opioid analgesia within 48 h. Secondary outcomes included opioid consumption, pain scores, inflammatory markers, blood glucose, quadriceps strength, and neurological safety. Results Time to first rescue opioid analgesia differed between groups (log-rank P < .001). Median time (95% CI) was 4.5 (4.5-5.5) h with placebo, 13.9 (12.5-14.7) h with intravenous dexamethasone, and 18.5 [16.5 to not reached (NR)] h with perineural dexamethasone. The proportions remaining opioid-free at 48 h were 0%, 23.3%, and 36.7%, respectively. Opioid consumption and pain scores were lower with both dexamethasone routes than with placebo; perineural administration resulted in the lowest opioid consumption and lower pain scores than intravenous administration at later timepoints. Perineural dexamethasone was associated with lower postoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, whereas intravenous dexamethasone was associated with higher blood glucose. No motor weakness or nerve injury occurred. Conclusions and relevance Perineural dexamethasone prolonged analgesia and reduced opioid requirements more than intravenous dexamethasone, without neurological or motor impairment. The inflammatory-marker findings were exploratory and do not establish independent clinical benefit. Clinical trial registration This trial was registered at ClinicalTrials.gov (NCT07180953). The record was released for review through the ClinicalTrials.gov Protocol Registration and Results System on September 12, 2025, before enrollment of the first participant on September 13, 2025, and was first publicly posted on September 17, 2025 following registry review.
EUVIMED